Table 2.
Patient, Donor, and Allograft Characteristics.
| Characteristic | Number | Percent |
|---|---|---|
|
| ||
| Age at HSCT, years | ||
| Median | 8 | |
| Range | 0.4-21 | |
|
| ||
| Male Recipients | 8 | 73 |
|
| ||
| Graft Source | ||
| Bone Marrow | 11 | 100 |
|
| ||
| Donor Source: | ||
| 10/10 HLA-matched unrelated | 6 | 55 |
| 5/8 Mismatched unrelated | 1 | 9 |
| HLA haploidentical related | 4 | 36 |
|
| ||
| Relationship of haplo donors | ||
| Parent | 3 | 75 |
| Sibling | 1 | 25 |
|
| ||
| GVHD Prophylaxis: | ||
| PT/Cy | 4 | 36 |
| PT/Cy + CNI + MMF | 7 | 64 |
|
| ||
| Donor age, years | ||
| Median | 30 | |
| Range | 19-43 | |
|
| ||
| Male donors | 6 | 55 |
|
| ||
| Female-into-male allografting | 3 | 27 |
|
| ||
| CMV at risk | 4 | 36 |
|
| ||
| Total nucleated cells/kilogram IBW infused | ||
| Median | 5.38 × 108 | |
| Range | 2.06 × 108 − 22.8 × 108 | |
|
| ||
| CD34+ cells/kilogram | ||
| Median | 5.98 × 106 | |
| Range | 2.09 × 106 − 11.0 × 106 | |
|
| ||
| ABO mismatch | ||
| Compatible | 8 | 73 |
| Major mismatch | 3 | 27 |
ABO, blood group type; CMV, cytomegalovirus; CNI, calcineurin inhibitor; GVHD, graft versus host disease; HSCT, hematopoietic stem cell transplant; HLA, human leukocyte antigen; IBW, ideal body weight; MMF, mycophenolate mofetil; PT/Cy, post-transplant cyclophosphamide.